Payment overview · 2025
General Payments
$3,105.44
115 reported records · 29 companies
Healthcare provider profile · identity verified
Said M Ibrahimi, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAN JOSE, CA · NPI 1376751321
Verified facts
What the public records show
CMS Open Payments records show Said M Ibrahimi, MD received $3,105.44 in general payments during 2025 across 115 reported records.
Neurocrine BioSciences, Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $691.17 | 22.3% | 22 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $450.89 | 14.5% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $270.53 | 8.7% | 11 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $260.35 | 8.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.22 | 8.0% | 11 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $181.74 | 5.8% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$134.32 | 4.3% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $108.39 | 3.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.54 | 2.9% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $77.55 | 2.5% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.45 | 2.1% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $53.36 | 1.7% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $47.85 | 1.5% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $46.29 | 1.5% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $33.97 | 1.1% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $31.90 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.55 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.87 | 0.9% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.45 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.38 | 0.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.80 | 0.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.60 | 0.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.50 | 0.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $23.14 | 0.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.06 | 0.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $22.39 | 0.7% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.47 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.88 | 0.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.83 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,093.73 | 114 |
| Education | $11.71 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $691.17 | 22 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $270.53 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $270.53 | 11 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $260.35 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $187.89 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $187.89 | 8 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $181.74 | 7 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $158.13 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $148.46 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $134.32 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $108.39 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $97.83 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $90.54 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $77.55 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $66.45 | 3 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $66.39 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $59.33 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $46.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $46.29 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 53 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
53 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 259 | 65 |
| Gabapentin | Gabapentin | 175 | 45 |
| Memantine Hcl | Memantine Hcl | 99 | 16 |
| Levetiracetam | Levetiracetam | 84 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 20 |
| Pregabalin | Pregabalin | 71 | 17 |
| Trazodone Hcl | Trazodone Hcl | 65 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 53 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 48 | 16 |
| Celecoxib | Celecoxib | 47 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Lacosamide | Lacosamide | 42 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 15 |
| Levetiracetam Er | Levetiracetam | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | 14 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Fycompa | Perampanel | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Neupro | Rotigotine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Nourianz | Istradefylline | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Zonisamide | Zonisamide | 19 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Vimpat | Lacosamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,105.44 · 115 records | Neurocrine BioSciences, Inc. | AMPYRA, APLENZIN, ARISTADA, AUSTEDO XR, BRIXADI, Briviact, EMGALITY, EPIDIOLEX, Fintepla, Hizentra, INBRIJA, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Leqembi, Motpoly XR, NURTEC ODT, Nayzilam, Ocrevus Zunovo, Omnipod, QULIPTA, REXULTI, Radicava, Rystiggo, SUBLOCADE, Senza, Symbravo, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VALTOCO, VYALEV, ZAVZPRET, ZEPOSIA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error